Langerhans Cell Histiocytosis and Associated Pathogenesis

Langerhans cell histiocytosis (LCH) is a rare disorder characterised by the clonal proliferation of Langerhans‐type dendritic cells that form granulomatous lesions in diverse organs, including bone, skin, lung and the central nervous system. Clinically, LCH spans a spectrum from isolated bone lesions to multisystem disease with risk‐organ involvement that can lead to significant morbidity. At the molecular level, aberrant activation of the RAS–RAF–MEK–ERK (MAPK) signalling pathway is the principal driver of pathogenic cell proliferation, most commonly through somatic BRAF V600E or MAP2K1 mutations. However, a subset of cases lacks these canonical mutations, indicating further genetic heterogeneity. The lesion microenvironment is shaped by cytokines, chemokines and immune cells, notably regulatory T cells, which contribute to lesion persistence by suppressing effective immune clearance. Therapeutic strategies now combine conventional chemotherapy with targeted inhibitors of MAPK pathway components, offering improved outcomes. Continued research aims to refine risk stratification, uncover additional driver mutations and understand the interplay between clonal Langerhans cells and the immune milieu, with the ultimate goal of personalised therapies for this enigmatic paediatric and adult disease.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Langerhans Cell Histiocytosis and Associated Pathogenesis publication trend

The graph below shows the total number of articles in langerhans cell histiocytosis and associated pathogenesis across all publications each year (not limited to Nature Index journals).

Technical terms

Langerhans cell: A specialised dendritic cell of myeloid origin that presents antigen in the skin and mucosa and is the pathological cell type in LCH.

MAPK pathway: A signalling cascade (RAS–RAF–MEK–ERK) that regulates cell proliferation and survival; its constitutive activation underlies LCH pathogenesis.

Somatic mutation: A genetic alteration acquired in non-germline cells that can drive clonal expansion in neoplastic conditions.

Granuloma: An organised aggregate of immune cells, including histiocytes and lymphocytes, formed in response to persistent inflammatory stimuli.

Regulatory T cell (T-reg): A subset of CD4+ T lymphocytes (characterised by FoxP3 expression) that suppress immune responses and contribute to lesion persistence in LCH.

References

1. Molecular and clinicopathologic characterization of pediatric histiocytoses. American Journal of Hematology (2023).
2. Expansion of Regulatory T Cells in Patients with Langerhans Cell Histiocytosis. PLOS Medicine (2007).
3. New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer (2017).